Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan'. Together they form a unique fingerprint.

Medicine & Life Sciences

Agriculture & Biology

Chemical Compounds